Brief: Pulse Biosciences First-In-Human Procedures With Its Novel Cellfx™ Nanosecond Pulsed Field Ablation (Nspfa™) Cardiac Catheter
20/12/2023 13:05
Dec 20 (Reuters) - Pulse Biosciences Inc PLSE.O :
* FIRST-IN-HUMAN PROCEDURES WITH ITS NOVEL CELLFX™
NANOSECOND
PULSED FIELD ABLATION (NSPFA™) CARDIAC CATHETER
Source text for Eikon: ID:nBw9sY58Sa
Further company coverage: PLSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulse Biosciences
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Pulse Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Pulse Biosciences Q2 net loss widens, cash position strengthens
Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants